Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study.

about

Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study.

Item

http://www.wikidata.org/entity/Q41561479

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Treatment and prognostic facto ...... se center retrospective study.

@en

type

Item

label

Treatment and prognostic facto ...... se center retrospective study.

@en

prefLabel

Treatment and prognostic facto ...... se center retrospective study.

@en

P1476

Treatment and prognostic facto ...... ese center retrospective study

@en

P2093

Baoan Chen

http://www.w3.org/2001/XMLSchema#string

Chengxin Luan

http://www.w3.org/2001/XMLSchema#string

Chong Gao

http://www.w3.org/2001/XMLSchema#string

Runzhe Chen

http://www.w3.org/2001/XMLSchema#string

Yujie Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials.

Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.

Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis.

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.

P304

373-380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S144405

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Xiao-Ping Zhang

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28883741

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

P932

5576706

http://www.w3.org/2001/XMLSchema#string